Research Foundation
Publications
Annually, the HDA Research Foundation undertakes research projects to educate and inform pharmaceutical supply chain stakeholders as they work daily to achieve healthcare efficiencies. The publications featured in this section may be downloaded at no additional cost from HDA's Resources webpage.
HDA Factbook: The Facts, Figures and Trends in Healthcare
In its 90th year, the HDA Factbook provides data metrics and benchmarking on the traditional pharmaceutical supply chain.
Sponsors: Apotex Corp. and Real Value Rx dba Hospital Pharmaceutical Consulting (Gold); and IQVIA, Pharmacy Frist and Teva Pharmaceuticals (Bronze)
Specialty Pharmaceutical Distribution: Facts, Figures and Trends
The Specialty Pharmaceutical Distribution: Facts, Figures and Trends report is a go-to resource for benchmarking data on specialty distribution and insight into the specialty pharmaceutical marketplace.
Sponsors: Genentech, A Member of the Roche Group and Value Drug Company (Gold); Amneal Pharmaceuticals, Associated Pharmacies, Inc. and Takeda Pharmaceuticals America, Inc. (Silver); Pharmacy First and Reliance Wholesale Inc.(Bronze).The Risks and Realities of Commercial Drug Importation
Based on expert interviews, literature reviews and quantitative data modeling, this report analyzes policies for their commercial feasibility, operational costs to the supply chain and overall effects on patient safety.
Sponsors: Anda, Inc., Novartis Pharmaceuticals Corporation (Platinum); Astellas Pharma US, Inc., Pfizer Inc. (Gold); Genentech, A Member of the Roche Group (Silver)
"Serialization Readiness Survey"
Conducted in summer 2019, this survey details pharmaceutical distributors and manufacturers’ preparedness to meet the product serialization requirements of the Drug Supply Chain Security Act (DSCSA).
Sponsors: ACG Inspection, Adents and LSPediA.
“The 340B Drug Pricing Program: Evolution and Looking Forward”
"Change Management: Best Practices in Contract and Chargeback Administration" Whitepaper
In the fall of 2018, the Foundation partnered with Rutgers University's Supply Chain Management Graduate Program. A team of five students, under the direction of Professor Irene Gerlovin, worked to identify and describe best practices for managing change in contract and chargeback administration due to system conversions and company mergers and acquisitions. The students interviewed subject matter experts, generated a survey, analyzed the data and developed a whitepaper. The final project was presented to HDA members through a webinar.
Sponsors: Amneal Pharmaceuticals, IQVIA and WDSrx - Woodfield Distribution, LLC.
The Role of Reverse Distribution
Through industry knowledge, interviews and survey results, The Role of Reverse Distribution report highlights the complex reverse distribution process and opportunities for future enhancement.
Sponsors: PharmaLink, Inc. (Silver); Guaranteed Returns (Bronze)
"Biosimilars: The State of the U.S. Market"
This report analyzes the current market for biosimilars in the U.S. through interviews conducted with senior executives from specialty pharmaceutical manufacturing and distribution companies.
"Understanding Pharmaceutical Distribution" Presentation
This turnkey PowerPoint presentation for presenters/trainers, as well as industry stakeholders, examines how the pharmaceutical supply chain operates and discusses the economics of traditional distribution.
"Understanding Specialty Distribution" Presentation
This turnkey PowerPoint presentation for presenters/trainers, as well as industry stakeholders, examines how the specialty pharmaceutical supply chain operates and discusses the economics of specialty pharmaceutical distribution.
The Role of Distributors in the U.S. Specialty Pharmaceuticals Value Chain
Through interviews, survey work and secondary data, The Role of Distributors in the U.S. Pharmaceuticals Value Chain explores the critical role distributors play to ensure the efficient and effective distribution of specialty medications.
Sponsors: Anda Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. ; H. D. Smith; and Takeda Pharmaceuticals America, Inc.
